nodes	percent_of_prediction	percent_of_DWPC	metapath
Ondansetron—HTR3A—Ligand-gated ion channel transport—GABRA2—conduct disorder	0.0807	0.0807	CbGpPWpGaD
Ondansetron—HTR4—Serotonin receptors—HTR2A—conduct disorder	0.0748	0.0748	CbGpPWpGaD
Ondansetron—HTR4—Monoamine GPCRs—DRD4—conduct disorder	0.0511	0.0511	CbGpPWpGaD
Ondansetron—HTR4—Amine ligand-binding receptors—DRD4—conduct disorder	0.0429	0.0429	CbGpPWpGaD
Ondansetron—HTR4—Monoamine GPCRs—HTR2A—conduct disorder	0.0333	0.0333	CbGpPWpGaD
Ondansetron—HTR4—G alpha (s) signalling events—CGA—conduct disorder	0.0316	0.0316	CbGpPWpGaD
Ondansetron—HTR1B—Serotonin receptors—HTR2A—conduct disorder	0.0313	0.0313	CbGpPWpGaD
Ondansetron—HTR4—Amine ligand-binding receptors—HTR2A—conduct disorder	0.028	0.028	CbGpPWpGaD
Ondansetron—HTR1A—Serotonin receptors—HTR2A—conduct disorder	0.0238	0.0238	CbGpPWpGaD
Ondansetron—HTR1B—Monoamine GPCRs—DRD4—conduct disorder	0.0213	0.0213	CbGpPWpGaD
Ondansetron—HTR1B—Amine ligand-binding receptors—DRD4—conduct disorder	0.0179	0.0179	CbGpPWpGaD
Ondansetron—HTR3A—Ion channel transport—GABRA2—conduct disorder	0.0175	0.0175	CbGpPWpGaD
Ondansetron—HTR1A—Monoamine GPCRs—DRD4—conduct disorder	0.0162	0.0162	CbGpPWpGaD
Ondansetron—HTR4—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.0151	0.0151	CbGpPWpGaD
Ondansetron—CYP1A2—Methylation—COMT—conduct disorder	0.0148	0.0148	CbGpPWpGaD
Ondansetron—HTR1B—Monoamine GPCRs—HTR2A—conduct disorder	0.0139	0.0139	CbGpPWpGaD
Ondansetron—HTR1A—Amine ligand-binding receptors—DRD4—conduct disorder	0.0137	0.0137	CbGpPWpGaD
Ondansetron—SLC47A2—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.0125	0.0125	CbGpPWpGaD
Ondansetron—HTR1B—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0117	0.0117	CbGpPWpGaD
Ondansetron—HTR4—GPCR ligand binding—CGA—conduct disorder	0.0115	0.0115	CbGpPWpGaD
Ondansetron—HTR3A—SIDS Susceptibility Pathways—SLC6A4—conduct disorder	0.0115	0.0115	CbGpPWpGaD
Ondansetron—HTR1A—Monoamine GPCRs—HTR2A—conduct disorder	0.0106	0.0106	CbGpPWpGaD
Ondansetron—HTR4—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00985	0.00985	CbGpPWpGaD
Ondansetron—CYP1A2—Estrogen metabolism—COMT—conduct disorder	0.00923	0.00923	CbGpPWpGaD
Ondansetron—HTR1A—Amine ligand-binding receptors—HTR2A—conduct disorder	0.00891	0.00891	CbGpPWpGaD
Ondansetron—HTR3A—SIDS Susceptibility Pathways—MAOA—conduct disorder	0.00863	0.00863	CbGpPWpGaD
Ondansetron—HTR4—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00844	0.00844	CbGpPWpGaD
Ondansetron—SLC47A1—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.00805	0.00805	CbGpPWpGaD
Ondansetron—KCNH2—SIDS Susceptibility Pathways—SLC6A4—conduct disorder	0.00795	0.00795	CbGpPWpGaD
Ondansetron—KCNH2—Neuronal System—GABRA2—conduct disorder	0.00786	0.00786	CbGpPWpGaD
Ondansetron—CYP2D6—Melatonin metabolism and effects—MAOA—conduct disorder	0.00739	0.00739	CbGpPWpGaD
Ondansetron—CYP3A4—Estrogen metabolism—COMT—conduct disorder	0.00712	0.00712	CbGpPWpGaD
Ondansetron—HTR3A—SIDS Susceptibility Pathways—HTR2A—conduct disorder	0.00704	0.00704	CbGpPWpGaD
Ondansetron—CYP3A7—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00651	0.00651	CbGpPWpGaD
Ondansetron—HTR4—GPCR downstream signaling—CGA—conduct disorder	0.00649	0.00649	CbGpPWpGaD
Ondansetron—HTR4—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00643	0.00643	CbGpPWpGaD
Ondansetron—HTR4—GPCR ligand binding—DRD4—conduct disorder	0.00643	0.00643	CbGpPWpGaD
Ondansetron—HTR1B—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.0063	0.0063	CbGpPWpGaD
Ondansetron—CYP1A2—Melatonin metabolism and effects—MAOA—conduct disorder	0.00626	0.00626	CbGpPWpGaD
Ondansetron—HTR3A—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.0061	0.0061	CbGpPWpGaD
Ondansetron—KCNH2—SIDS Susceptibility Pathways—MAOA—conduct disorder	0.00598	0.00598	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—CGA—conduct disorder	0.00589	0.00589	CbGpPWpGaD
Ondansetron—OPRM1—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00556	0.00556	CbGpPWpGaD
Ondansetron—HTR4—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00551	0.00551	CbGpPWpGaD
Ondansetron—HTR1A—SIDS Susceptibility Pathways—SLC6A4—conduct disorder	0.00499	0.00499	CbGpPWpGaD
Ondansetron—KCNH2—SIDS Susceptibility Pathways—HTR2A—conduct disorder	0.00488	0.00488	CbGpPWpGaD
Ondansetron—HTR1A—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.0048	0.0048	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—CGA—conduct disorder	0.0048	0.0048	CbGpPWpGaD
Ondansetron—CYP2E1—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00472	0.00472	CbGpPWpGaD
Ondansetron—CYP3A5—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00471	0.00471	CbGpPWpGaD
Ondansetron—HTR1B—G alpha (i) signalling events—DRD4—conduct disorder	0.00444	0.00444	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—CGA—conduct disorder	0.00423	0.00423	CbGpPWpGaD
Ondansetron—HTR4—GPCR ligand binding—HTR2A—conduct disorder	0.00419	0.00419	CbGpPWpGaD
Ondansetron—HTR1B—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00412	0.00412	CbGpPWpGaD
Ondansetron—OPRM1—G alpha (i) signalling events—DRD4—conduct disorder	0.00391	0.00391	CbGpPWpGaD
Ondansetron—KCNH2—Neuronal System—COMT—conduct disorder	0.00378	0.00378	CbGpPWpGaD
Ondansetron—KCNH2—Neuronal System—MAOA—conduct disorder	0.00376	0.00376	CbGpPWpGaD
Ondansetron—HTR1A—SIDS Susceptibility Pathways—MAOA—conduct disorder	0.00375	0.00375	CbGpPWpGaD
Ondansetron—HTR3A—SIDS Susceptibility Pathways—EP300—conduct disorder	0.00373	0.00373	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—CGA—conduct disorder	0.00365	0.00365	CbGpPWpGaD
Ondansetron—OPRM1—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00363	0.00363	CbGpPWpGaD
Ondansetron—HTR4—GPCR downstream signaling—DRD4—conduct disorder	0.00363	0.00363	CbGpPWpGaD
Ondansetron—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00353	0.00353	CbGpPWpGaD
Ondansetron—CYP3A7—Biological oxidations—COMT—conduct disorder	0.00348	0.00348	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—CGA—conduct disorder	0.00348	0.00348	CbGpPWpGaD
Ondansetron—CYP3A7—Biological oxidations—MAOA—conduct disorder	0.00346	0.00346	CbGpPWpGaD
Ondansetron—CYP3A7—Metapathway biotransformation—COMT—conduct disorder	0.00344	0.00344	CbGpPWpGaD
Ondansetron—HTR1A—G alpha (i) signalling events—DRD4—conduct disorder	0.00338	0.00338	CbGpPWpGaD
Ondansetron—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00335	0.00335	CbGpPWpGaD
Ondansetron—CYP2C9—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00332	0.00332	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—DRD4—conduct disorder	0.0033	0.0033	CbGpPWpGaD
Ondansetron—HTR1A—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00314	0.00314	CbGpPWpGaD
Ondansetron—OPRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00311	0.00311	CbGpPWpGaD
Ondansetron—HTR1A—SIDS Susceptibility Pathways—HTR2A—conduct disorder	0.00306	0.00306	CbGpPWpGaD
Ondansetron—CYP1A2—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00284	0.00284	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—WASF1—conduct disorder	0.00279	0.00279	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—CGA—conduct disorder	0.00271	0.00271	CbGpPWpGaD
Ondansetron—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00269	0.00269	CbGpPWpGaD
Ondansetron—HTR1B—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00269	0.00269	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—DRD4—conduct disorder	0.00269	0.00269	CbGpPWpGaD
Ondansetron—CYP1A2—Phase II conjugation—COMT—conduct disorder	0.00259	0.00259	CbGpPWpGaD
Ondansetron—KCNH2—SIDS Susceptibility Pathways—EP300—conduct disorder	0.00258	0.00258	CbGpPWpGaD
Ondansetron—CYP2E1—Biological oxidations—COMT—conduct disorder	0.00252	0.00252	CbGpPWpGaD
Ondansetron—CYP3A5—Biological oxidations—COMT—conduct disorder	0.00252	0.00252	CbGpPWpGaD
Ondansetron—CYP2E1—Biological oxidations—MAOA—conduct disorder	0.00251	0.00251	CbGpPWpGaD
Ondansetron—CYP3A5—Biological oxidations—MAOA—conduct disorder	0.0025	0.0025	CbGpPWpGaD
Ondansetron—CYP2E1—Metapathway biotransformation—COMT—conduct disorder	0.00249	0.00249	CbGpPWpGaD
Ondansetron—CYP3A5—Metapathway biotransformation—COMT—conduct disorder	0.00248	0.00248	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—CGA—conduct disorder	0.00246	0.00246	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—CGA—conduct disorder	0.00239	0.00239	CbGpPWpGaD
Ondansetron—OPRM1—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00237	0.00237	CbGpPWpGaD
Ondansetron—HTR4—GPCR downstream signaling—HTR2A—conduct disorder	0.00237	0.00237	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—DRD4—conduct disorder	0.00237	0.00237	CbGpPWpGaD
Ondansetron—HTR1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.0023	0.0023	CbGpPWpGaD
Ondansetron—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00219	0.00219	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—CGA—conduct disorder	0.00217	0.00217	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—HTR2A—conduct disorder	0.00215	0.00215	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—CGA—conduct disorder	0.00206	0.00206	CbGpPWpGaD
Ondansetron—HTR1A—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00205	0.00205	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—DRD4—conduct disorder	0.00205	0.00205	CbGpPWpGaD
Ondansetron—OPRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00203	0.00203	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—DRD4—conduct disorder	0.00195	0.00195	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—CGA—conduct disorder	0.00187	0.00187	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—conduct disorder	0.00187	0.00187	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor—EP300—conduct disorder	0.00187	0.00187	CbGpPWpGaD
Ondansetron—CYP2D6—Biological oxidations—COMT—conduct disorder	0.00179	0.00179	CbGpPWpGaD
Ondansetron—CYP2D6—Biological oxidations—MAOA—conduct disorder	0.00178	0.00178	CbGpPWpGaD
Ondansetron—CYP2C9—Biological oxidations—COMT—conduct disorder	0.00178	0.00178	CbGpPWpGaD
Ondansetron—CYP2D6—Metapathway biotransformation—COMT—conduct disorder	0.00177	0.00177	CbGpPWpGaD
Ondansetron—CYP2C9—Biological oxidations—MAOA—conduct disorder	0.00176	0.00176	CbGpPWpGaD
Ondansetron—HTR1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00175	0.00175	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—HTR2A—conduct disorder	0.00175	0.00175	CbGpPWpGaD
Ondansetron—CYP2C9—Metapathway biotransformation—COMT—conduct disorder	0.00175	0.00175	CbGpPWpGaD
Ondansetron—HTR1A—SIDS Susceptibility Pathways—EP300—conduct disorder	0.00162	0.00162	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—HTR2A—conduct disorder	0.00155	0.00155	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—DRD4—conduct disorder	0.00152	0.00152	CbGpPWpGaD
Ondansetron—CYP1A2—Biological oxidations—COMT—conduct disorder	0.00152	0.00152	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.00151	0.00151	CbGpPWpGaD
Ondansetron—CYP1A2—Biological oxidations—MAOA—conduct disorder	0.00151	0.00151	CbGpPWpGaD
Ondansetron—CYP1A2—Metapathway biotransformation—COMT—conduct disorder	0.0015	0.0015	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CGA—conduct disorder	0.00145	0.00145	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—DRD4—conduct disorder	0.00138	0.00138	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—DRD4—conduct disorder	0.00134	0.00134	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—HTR2A—conduct disorder	0.00133	0.00133	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—CGA—conduct disorder	0.00132	0.00132	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.00129	0.00129	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CGA—conduct disorder	0.00128	0.00128	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—HTR2A—conduct disorder	0.00127	0.00127	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—DRD4—conduct disorder	0.00122	0.00122	CbGpPWpGaD
Ondansetron—CYP3A4—Biological oxidations—COMT—conduct disorder	0.00117	0.00117	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—WASF1—conduct disorder	0.00117	0.00117	CbGpPWpGaD
Ondansetron—CYP3A4—Biological oxidations—MAOA—conduct disorder	0.00116	0.00116	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—DRD4—conduct disorder	0.00116	0.00116	CbGpPWpGaD
Ondansetron—CYP3A4—Metapathway biotransformation—COMT—conduct disorder	0.00115	0.00115	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CGA—conduct disorder	0.00111	0.00111	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—DRD4—conduct disorder	0.00105	0.00105	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—WASF1—conduct disorder	0.00103	0.00103	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—HTR2A—conduct disorder	0.00099	0.00099	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—CGA—conduct disorder	0.000956	0.000956	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—CGA—conduct disorder	0.000954	0.000954	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—HTR2A—conduct disorder	0.000899	0.000899	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—WASF1—conduct disorder	0.000888	0.000888	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—HTR2A—conduct disorder	0.000874	0.000874	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—DRD4—conduct disorder	0.000814	0.000814	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—HTR2A—conduct disorder	0.000794	0.000794	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—HTR2A—conduct disorder	0.000754	0.000754	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—DRD4—conduct disorder	0.000719	0.000719	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—HTR2A—conduct disorder	0.000685	0.000685	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CGA—conduct disorder	0.000678	0.000678	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—EP300—conduct disorder	0.000674	0.000674	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CGA—conduct disorder	0.000672	0.000672	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—DRD4—conduct disorder	0.00062	0.00062	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—COMT—conduct disorder	0.000596	0.000596	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—MAOA—conduct disorder	0.000592	0.000592	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CGA—conduct disorder	0.000575	0.000575	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—HTR2A—conduct disorder	0.000531	0.000531	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—HTR2A—conduct disorder	0.000469	0.000469	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CGA—conduct disorder	0.000444	0.000444	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—COMT—conduct disorder	0.000432	0.000432	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—COMT—conduct disorder	0.000431	0.000431	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—MAOA—conduct disorder	0.000428	0.000428	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—MAOA—conduct disorder	0.000428	0.000428	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—HTR2A—conduct disorder	0.000405	0.000405	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—COMT—conduct disorder	0.000306	0.000306	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—MAOA—conduct disorder	0.000304	0.000304	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—COMT—conduct disorder	0.000304	0.000304	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—MAOA—conduct disorder	0.000301	0.000301	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.000292	0.000292	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—EP300—conduct disorder	0.000281	0.000281	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—COMT—conduct disorder	0.000259	0.000259	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—MAOA—conduct disorder	0.000258	0.000258	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—EP300—conduct disorder	0.000255	0.000255	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.00025	0.00025	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—EP300—conduct disorder	0.000248	0.000248	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—EP300—conduct disorder	0.000214	0.000214	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—COMT—conduct disorder	0.0002	0.0002	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—MAOA—conduct disorder	0.000199	0.000199	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—EP300—conduct disorder	0.000185	0.000185	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—EP300—conduct disorder	0.000185	0.000185	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—EP300—conduct disorder	0.000131	0.000131	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—EP300—conduct disorder	0.00013	0.00013	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—EP300—conduct disorder	0.000111	0.000111	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—EP300—conduct disorder	8.59e-05	8.59e-05	CbGpPWpGaD
